Coadministration of platelet-derived growth factor-BB and vascular endothelial growth factor with bladder acellular matrix enhances smooth muscle regeneration and vascularization for bladder augmentation in a rabbit model.
Tissue-engineering techniques have brought a great hope for bladder repair and reconstruction. The crucial requirements of a tissue-engineered bladder are bladder smooth muscle regeneration and vascularization. In this study, partial rabbit bladder (4×5 cm) was removed and replaced with a porcine bladder acellular matrix (BAM) that was equal in size. BAM was incorporated with platelet-derived growth factor-BB (PDGF-BB) and vascular endothelial growth factor (VEGF) in the experimental group while with no bioactive factors in the control group. The bladder tissue strip contractility in the experimental rabbits was better than that in the control ones postoperation. Histological evaluation revealed that smooth muscle regeneration and vascularization in the experimental group were significantly improved compared with those in the control group (p<0.05), while multilayered urothelium was formed in both groups. Muscle strip contractility of neobladder in the experimental group exhibited significantly better than that in the control (p<0.05) assessed with electrical field stimulation and carbachol interference. The activity of matrix metalloproteinase-2 (MMP-2) and MMP-9 in the native bladder tissue around tissue-engineered neobladder in the experimental group was significantly higher than that in the control (p<0.05). This work suggests that smooth muscle regeneration and vascularization in tissue-engineered neobladder and recovery of bladder function could be enhanced by PDGF-BB and VEGF incorporated within BAM, which promoted the upregulation of the activity of MMP-2 and MMP-9 of native bladder tissue around the tissue-engineered neobladder.
Department of Urology, Nanjing University School of Medicine, Affiliated Drum Tower Hospital, Nanjing, China.
Liuhua
L
Zhou
Bin
B
Yang
Chao
C
Sun
Xuefeng
X
Qiu
Zeyu
Z
Sun
Yun
Y
Chen
Yuanyuan
Y
Zhang
Yutian
Y
Dai
D000818:Animals; D000077214:Becaplermin; D001705:Bioprosthesis; D001808:Blood Vessels / Q000254:growth & development*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005109:Extracellular Matrix / Q000637:transplantation*; D009130:Muscle, Smooth / Q000254:growth & development*; D020574:Proto-Oncogene Proteins c-sis / Q000008:administration & dosage*; D011817:Rabbits; D012038:Regeneration; D013552:Swine; D023822:Tissue Engineering / Q000295:instrumentation / Q000379:methods; D001743:Urinary Bladder / Q000098:blood supply / Q000254:growth & development* / Q000648:ultrastructure; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage*
D004338:Drug Combinations; D020574:Proto-Oncogene Proteins c-sis; D042461:Vascular Endothelial Growth Factor A; D000077214:Becaplermin